Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1962 1
1964 1
1965 2
1969 5
1970 1
1971 1
1972 2
1974 2
1975 1
1976 2
1977 1
1979 1
1982 2
1983 4
1984 6
1985 5
1986 5
1987 3
1988 4
1989 3
1990 6
1991 11
1992 5
1993 10
1994 5
1995 8
1996 9
1997 7
1998 7
1999 11
2000 15
2001 21
2002 18
2003 8
2004 9
2005 15
2006 18
2007 19
2008 28
2009 19
2010 20
2011 24
2012 21
2013 19
2014 31
2015 35
2016 26
2017 28
2018 28
2019 49
2020 39
2021 58
2022 63
2023 47
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

727 results

Results by year

Filters applied: . Clear all
Page 1
Inhibitor eradication and treatment for acquired hemophilia A.
Franchini M, Focosi D. Franchini M, et al. Expert Rev Hematol. 2024 May 9:1-8. doi: 10.1080/17474086.2024.2352505. Online ahead of print. Expert Rev Hematol. 2024. PMID: 38708599 Review.
INTRODUCTION: Acquired hemophilia A (AHA) is a rare hemorrhagic autoimmune disorder characterized by autoantibodies against coagulation factor VIII (FVIII). In approximately half of the cases AHA does not recognize any cause (idiopathic form), while in the ot …
INTRODUCTION: Acquired hemophilia A (AHA) is a rare hemorrhagic autoimmune disorder characterized by autoantibodies aga …
Emicizumab for acquired hemophilia A: Report of two cases and dosing strategies.
Ahmed F, Kasianchyk M, Moreno A, Chang S, Maharaj S. Ahmed F, et al. EJHaem. 2024 Mar 15;5(2):387-391. doi: 10.1002/jha2.878. eCollection 2024 Apr. EJHaem. 2024. PMID: 38633111 Free PMC article.
Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder caused by autoantibodies against FVIII. ...
Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder caused by autoantibodies against FVIII. ...
Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients.
Lévesque H, Viallard JF, Houivet E, Bonnotte B, Voisin S, Le Cam-Duchez V, Maillot F, Lambert M, Liozon E, Hervier B, Fain O, Guillet B, Schmidt J, Luca LE, Ebbo M, Ferreira-Maldent N, Babuty A, Sailler L, Duffau P, Barbay V, Audia S, Benichou J, Graveleau J, Benhamou Y; CREHA Study investigators on behalf the scientific committee of the “Société Nationale Française de Médecine Interne” (SNFMI – French National Society of Internal Medicine). Lévesque H, et al. Thromb Res. 2024 May;237:79-87. doi: 10.1016/j.thromres.2024.03.012. Epub 2024 Mar 15. Thromb Res. 2024. PMID: 38555718 Free article. Clinical Trial.
BACKGROUND: Acquired hemophilia A (AHA) is a rare autoimmune disorder due to autoantibodies against Factor VIII, with a high mortality risk. ...
BACKGROUND: Acquired hemophilia A (AHA) is a rare autoimmune disorder due to autoantibodies against Factor VIII, with a …
An observational study of haemophilia A patients without inhibitors using the French national claims (SNDS) database.
Trossaërt M, Falk A, Gautier L, Kragh N, Van Hinloopen O, Varin R. Trossaërt M, et al. Hematology. 2024 Dec;29(1):2320610. doi: 10.1080/16078454.2024.2320610. Epub 2024 Mar 6. Hematology. 2024. PMID: 38445826
OBJECTIVES: To describe clinical characteristics, factor consumption, and events of interest in patients with haemophilia A without inhibitors receiving prophylaxis in France, and the clinical impact of switching to Elocta in this population. ...CONCLUSION: This study prov …
OBJECTIVES: To describe clinical characteristics, factor consumption, and events of interest in patients with haemophilia A without i …
Innovative Therapies for Acquired Hemophilia A.
Franchini M, Focosi D. Franchini M, et al. Semin Thromb Hemost. 2024 Feb 23. doi: 10.1055/s-0044-1779737. Online ahead of print. Semin Thromb Hemost. 2024. PMID: 38395066
Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder which can be life-threatening. ...Disease onset may be idiopathic (approximately half of the cases) or triggered by autoimmune disorders, cancers, drugs, infections, or pregnancy. Besid …
Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder which can be life-threatening. ...Disease onset may …
Inflammation and autoimmunity are interrelated in patients with sickle cell disease at a steady-state condition: implications for vaso-occlusive crisis, pain, and sensory sensitivity.
Li W, Pucka AQ, Debats C, Reyes BA, Syed F, O'Brien ARW, Mehta R, Manchanda N, Jacob SA, Hardesty BM, Greist A, Harte SE, Harris RE, Yu Q, Wang Y. Li W, et al. Front Immunol. 2024 Feb 1;15:1288187. doi: 10.3389/fimmu.2024.1288187. eCollection 2024. Front Immunol. 2024. PMID: 38361924 Free PMC article.
This study aimed to comprehensively analyze inflammatory and autoimmune characteristics of patients with sickle cell disease (SCD) at a steady-state condition (StSt) compared to healthy controls (HCs) to explore the pathogenesis of StSt and its impact on patients' well-bei …
This study aimed to comprehensively analyze inflammatory and autoimmune characteristics of patients with sickle cell disease (SCD) at …
PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review.
Moore DC, Elmes JB, Arnall JR, Strassel SA, Patel JN. Moore DC, et al. Int Immunopharmacol. 2024 Mar 10;129:111606. doi: 10.1016/j.intimp.2024.111606. Epub 2024 Feb 14. Int Immunopharmacol. 2024. PMID: 38359661
Immune-mediated hematologic toxicities have been reported, but are less well-described in the literature. Immune thrombocytopenia (ITP) is a rare autoimmune, hematologic adverse event that has been reported with PD-1/PD-L1 inhibitors. ...
Immune-mediated hematologic toxicities have been reported, but are less well-described in the literature. Immune thrombocytopenia (ITP) is a …
Excellent response to treatment with hydroxychloroquine in pediatric patients with SLE-related immune thrombocytopenia.
Brik-Simon D, Efros O, Levinsky Y, Amarilyo G, Tirosh I, Levy-Mendelovich S, Steinberg-Shemer O, Izraeli S, Yacobovich J, Gilad O. Brik-Simon D, et al. Pediatr Blood Cancer. 2024 May;71(5):e30911. doi: 10.1002/pbc.30911. Epub 2024 Feb 13. Pediatr Blood Cancer. 2024. PMID: 38348516
BACKGROUND: Pediatric immune thrombocytopenia (ITP) may precede systemic autoimmune disorders. In adolescent patients with ITP, routine screening for systemic lupus erythematosus (SLE) may be performed by testing for antinuclear antibody (ANA) titer. ...
BACKGROUND: Pediatric immune thrombocytopenia (ITP) may precede systemic autoimmune disorders. In adolescent patients with ITP, routi …
Immune tolerance promotion by LSEC-specific lentiviral vector-mediated expression of the transgene regulated by the stabilin-2 promoter.
Borroni E, Borsotti C, Cirsmaru RA, Kalandadze V, Famà R, Merlin S, Brown B, Follenzi A. Borroni E, et al. Mol Ther Nucleic Acids. 2024 Jan 17;35(1):102116. doi: 10.1016/j.omtn.2024.102116. eCollection 2024 Mar 12. Mol Ther Nucleic Acids. 2024. PMID: 38333675 Free PMC article.
Finally, we show that our delivery system can partially and permanently restore FVIII activity in a mouse model of severe hemophilia A without the formation of anti-FVIII antibodies. Overall, our findings establish the suitability of STAB2p for long-term LSEC-restri …
Finally, we show that our delivery system can partially and permanently restore FVIII activity in a mouse model of severe hemophilia …
Global comment on the use of hydroxychloroquine during the periconception period and pregnancy in women with autoimmune diseases.
Schreiber K, Giles I, Costedoat-Chalumeau N, Nelson-Piercy C, Dolhain RJ, Mosca M, Förger F, Fischer-Betz R, Molto A, Tincani A, Pasquier E, Marin B, Elefant E, Salmon J, Bermas BL, Sammaritano L, Clowse MEB, Chambers C, Buyon J, Inoue SA, Agmon-Levin N, Aguilera S, Emadi SA, Andersen J, Andrade D, Antovic A, Arnaud L, Christiansen AA, Avcin T, Badreh-Wirström S, Bertsias G, Bini I, Bobirca A, Branch W, Brucato A, Bultink I, Capela S, Cecchi I, Cervera R, Chighizola C, Cobilinschi C, Cuadrado MJ, Dey D, Etomi O, Espinosa G, Flint J, Fonseca JE, Fritsch-Stork R, Gerosa M, Glintborg B, Skorpen CG, Goulden B, Graversgaard C, Gunnarsson I, Gupta L, Hetland M, Hodson K, Hunt BJ, Isenberg D, Jacobsen S, Khamashta M, Levy R, Linde L, Lykke J, Meissner Y, Moore L, Morand E, Navarra S, Opris-Belinski D, Østensen M, Ozawa H, Perez-Garcia LF, Petri M, Pons-Estel GJ, Radin M, Raio L, Rottenstreich A, Ruiz-Irastorza G, Tunjić SR, Rygg M, Sciascia S, Strangfeld A, Svenungsson E, Tektonidou M, Troldborg A, Vinet E, Vojinovic J, Voss A, Wallenius M, Andreoli L. Schreiber K, et al. Lancet Rheumatol. 2023 Sep;5(9):e501-e506. doi: 10.1016/S2665-9913(23)00215-1. Epub 2023 Aug 21. Lancet Rheumatol. 2023. PMID: 38251494 No abstract available.
727 results